The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.

The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.

The present invention provides methods for inducing tolerance and/or suppressing an immune response to an antigen by passing a cell suspension containing an anucleate cell through a constriction, wherein the constriction deforms the cell thereby causing a perturbation of the cell such that an antigen and/or tolerogenic factor enters the cell. In some embodiments, the anucleate cell is delivered to an individual and the antigen is delivered to and processed in a tolerogenic environment to induce tolerance and/or suppress an immune response to the antigen.

Described herein is a method for producing blood progenitor (hematopoietic progenitor cells) and T cell progenitor cells and to cells produced or obtainable by the process and the use of said cells, the method including: (a) optionally subjecting pluripotent stem cells under conditions that direct the cells to become mesoderm and subsequently hemogenic endothelial cells; and (b) directing hemogenic endothelial cells to differentiate into blood progenitor cells, preferably defined blood progenitor cells) using a media formulation designed to promote endothelial to hematopoietic transition (EHT) while being cultured on a surface functionalised with ligands designed to activate the Notch signaling pathway. In some aspects the ligands are Notch ligands, such as DLL4 and integrin ligands, such as integrin ?4?1 ligand or VCAM1.

Disclosed are methods of preparing CD34+CD43+ hematopoietic progenitor cells (HPC) in vitro according to embodiments of the invention. Also disclosed are methods of differentiating CD34+CD43+ hematopoietic progenitor cells to hematopoietic lineage cells according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e.g., cancer, according to embodiments of the invention.

Embodiments described herein relate to suppressing the immune response locally within tissue transplants and certain conditions improperly affecting the immune system using optogenetically controlled cells. More specifically, embodiments described herein provide for localized immunosuppression surrounding tissue transplants and illness locations as an alternative to systemically suppressing a patient's entire immune system. Methods include implantation of optogenetically modified immunosuppressive cells that are configured to alter their biological activity to enhance their immunosuppressive activity in response to exposure of wavelengths of light in the red and near-infrared window spectral region (620-900 nm).

The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.

The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.

Methods are provided for treating blood monocytes to produce functional antigen presenting dendritic cells. An extracorporeal quantity of a subject's blood is treated to separate the blood and produce a leukocyte concentrate comprising monocytes and plasma containing proteins. The leukocyte concentrate comprising monocytes and plasma containing proteins is pumped through a plastic treatment device, such as a photopheresis device. The resulting treated cells may be incubated for a sufficient period of time to allow the monocytes to form dendritic cells, or the treated cells may be reinfused directly to the subject.

The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.